Subcutaneous Lecanemab Maintenance Dosing for Alzheimer's Supported by New Data

(MedPage Today) — TORONTO — An investigational subcutaneous autoinjector showed comparable efficacy and safety to the IV formulation of lecanemab (Leqembi) for maintenance treatment in early Alzheimer’s disease, researchers said here.
Continued…

Source link : https://www.medpagetoday.com/meetingcoverage/aaic/116807

Author :

Publish date : 2025-08-03 17:53:00

Copyright for syndicated content belongs to the linked Source.

M	T	W	T	F	S	S
				1	2	3
4	5	6	7	8	9	10
11	12	13	14	15	16	17
18	19	20	21	22	23	24
25	26	27	28	29	30	31

Subcutaneous Lecanemab Maintenance Dosing for Alzheimer’s Supported by New Data

Advice to Young Physicians: Avoid the Headhunters

‘I Can’t Pee Like I Used to Pee’: What We Heard This Week

Related Posts

‘I Can’t Pee Like I Used to Pee’: What We Heard This Week

Advice to Young Physicians: Avoid the Headhunters

Artists help Tamworth pupils and cancer centre users create murals

Combination Therapy for AMD Fails to Improve Vision Versus Single Drug

Questions Abound About Treating AMD, Geographic Atrophy at the Same Time

Which Physicians Have a Higher Mortality Risk?

‘I Can’t Pee Like I Used to Pee’: What We Heard This Week

Subcutaneous Lecanemab Maintenance Dosing for Alzheimer’s Supported by New Data

Advice to Young Physicians: Avoid the Headhunters

Artists help Tamworth pupils and cancer centre users create murals

Combination Therapy for AMD Fails to Improve Vision Versus Single Drug

Questions Abound About Treating AMD, Geographic Atrophy at the Same Time

Which Physicians Have a Higher Mortality Risk?

HPV and Skin Cancer; Polygenic Risk Score for Obesity; Rare Flu Complication in Kids

Categories

Archives